ResearcherAssistance Publique – Hôpitaux de ParisNo recent work listed
Philippe R Rougier
Matched on OpenAlex author ID A5108355909. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 30
2011: 1 paper · 2012: 3 papers · 2013: 1 paper · 2014: 1 paper
Papers 6
- Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. Co-author DOI 10.1016/j.clinre.2014.01.005↗
- Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine… Co-author DOI 10.1016/j.ejca.2013.04.002↗
- Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Co-author DOI 10.1053/j.gastro.2012.06.006↗
- Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mdr617↗
- Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Last author DOI 10.1093/annonc/mds224↗
- [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results … Co-author DOI 10.1016/j.canrad.2010.10.001↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jean‐Baptiste Bachet · 3 shared papers, 2012 · strength 0.09
- Paper Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. DOI 10.1093/annonc/mds224↗
- Paper Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in res… DOI 10.1093/annonc/mdr617↗
- Paper Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for… DOI 10.1053/j.gastro.2012.06.006↗
- Pascal R. Hammel · 3 shared papers, 2011–2012 · strength 0.07
- Paper Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in res… DOI 10.1093/annonc/mdr617↗
- Paper Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for… DOI 10.1053/j.gastro.2012.06.006↗
- Paper [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versu… DOI 10.1016/j.canrad.2010.10.001↗
- Raphaël Maréchal · 2 shared papers, 2012 · strength 0.05
- Paper Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in res… DOI 10.1093/annonc/mdr617↗
- Paper Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for… DOI 10.1053/j.gastro.2012.06.006↗
- Jean Closset · 2 shared papers, 2012 · strength 0.05
- Paper Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in res… DOI 10.1093/annonc/mdr617↗
- Paper Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for… DOI 10.1053/j.gastro.2012.06.006↗
- Pieter Demetter · 2 shared papers, 2012 · strength 0.05
- Paper Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in res… DOI 10.1093/annonc/mdr617↗
- Paper Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for… DOI 10.1053/j.gastro.2012.06.006↗
- Magali Svrcek · 2 shared papers, 2012 · strength 0.05
- Paper Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in res… DOI 10.1093/annonc/mdr617↗
- Paper Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for… DOI 10.1053/j.gastro.2012.06.006↗
- Jean‐Luc Van Laethem · 2 shared papers, 2012 · strength 0.05
- Paper Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in res… DOI 10.1093/annonc/mdr617↗
- Paper Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for… DOI 10.1053/j.gastro.2012.06.006↗
- Anne Couvelard · 2 shared papers, 2012 · strength 0.05
- Paper Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in res… DOI 10.1093/annonc/mdr617↗
- Paper Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for… DOI 10.1053/j.gastro.2012.06.006↗
- François Paye · 2 shared papers, 2012 · strength 0.05
- Paper Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in res… DOI 10.1093/annonc/mdr617↗
- Paper Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for… DOI 10.1053/j.gastro.2012.06.006↗
- Alain Sauvanet · 2 shared papers, 2012 · strength 0.05
- Paper Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in res… DOI 10.1093/annonc/mdr617↗
- Paper Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for… DOI 10.1053/j.gastro.2012.06.006↗
- Thierry André · 2 shared papers, 2012 · strength 0.05
- Paper Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in res… DOI 10.1093/annonc/mdr617↗
- Paper Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for… DOI 10.1053/j.gastro.2012.06.006↗
- Christophe Louvet · 2 shared papers, 2012 · strength 0.05
- Paper Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in res… DOI 10.1093/annonc/mdr617↗
- Paper Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for… DOI 10.1053/j.gastro.2012.06.006↗
- Franck Bonnetain · 2 shared papers, 2011–2012 · strength 0.05
- Paper Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in res… DOI 10.1093/annonc/mdr617↗
- Paper [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versu… DOI 10.1016/j.canrad.2010.10.001↗
- Thomas Theodor Werner Seufferlein · 1 shared paper, 2012 · strength 0.04
- Eric Van Cutsem · 1 shared paper, 2012 · strength 0.04
- Alix Portal · 1 shared paper, 2014 · strength 0.04
- Aziz Zaanan · 1 shared paper, 2014 · strength 0.04
- Julien Taı̈eb · 1 shared paper, 2014 · strength 0.04
- Simon Pernot · 1 shared paper, 2014 · strength 0.04
- Armando Santoro · 1 shared paper, 2013 · strength 0.03
- Petr Karásek · 1 shared paper, 2013 · strength 0.03
- Hanno B. Riess · 1 shared paper, 2013 · strength 0.03
- Philip A. Philip · 1 shared paper, 2013 · strength 0.03
- Charles Dumontet · 1 shared paper, 2012 · strength 0.02
- Jacques M.E. Deviere · 1 shared paper, 2012 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.